|
|
1) Gehring W, Gloor M. Treatment of the atopic dermatitis with a water-in-oil
emulsion with or without the addition of hydrocortisone-results of a controlled
double-blind randomized study using clinical evaluation and bioengineering
methods. H+G Zeitschrift Fur Hautkrankheiten. 1996;71:554-60.
2) Sears HW, Bailer JW, Yeadon A. Efficacy and safety of hydrocortisone
buteprate 0.1% cream in patients with atopic dermatitis.@Clin Ther. 1997 Jul-Aug;19(4):710-9.
3) Korting HC, Schafer-Korting M, Klovekorn W, Klovekorn G, Martin C, Laux
P. Comparative efficacy of hamamelis distillate and hydrocortisone cream in
atopic eczema. Eur J Clin Pharmacol. 1995;48(6):461-5.
4) Bleehen SS, Chu AC, Hamann I, Holden C, Hunter JA, Marks R. Fluticasone
propionate 0.05% cream in the treatment of atopic eczema: a multicentre study
comparing once-daily treatment and once-daily vehicle cream application versus
twice-daily treatment. Br J Dermatol. 1995 Oct;133(4):592-7.
5) Stalder JF, Fleury M, Sourisse M, Rostin M, Pheline F, Litoux P. Local steroid
therapy and bacterial skin flora in atopic dermatitis. Br J Dermatol. 1994
Oct;131(4):536-40.
6) Lupton ES, Abbrecht MM, Brandon ML. Short-term topical corticosteroid therapy
(halcinonide ointment) in the management of atopic dermatitis. Cutis. 1982
Nov;30(5):671-5.
7) Sudilovsky A, Muir JG, Bocobo FC. A comparison of single and multiple applications
of halcinonide cream. Int J Dermatol. 1981 Nov;20(9):609-13.
8) Wahlgren CF, Hagermark O, Bergstrom R, Hedin B. Evaluation of a new method
of assessing pruritus and antipruritic drugs. Skin Pharmacol. 1988;1(1):3-13.
9) Van Der Meer JB, Glazenburg EJ, Mulder PG, Eggink HF, Coenraads PJ. The
management of moderate to severe atopic dermatitis in adults with topical fluticasone
propionate. The Netherlands Adult Atopic Dermatitis Study Group. Br J Dermatol.
1999 Jun;140(6):1114-21.
10) Sefton J, Loder JS, Kyriakopoulos AA. Clinical evaluation of hydrocortisone
valerate 0.2% ointment. Clin Ther. 1984;6(3):282-93.
11) Lebwohl M, Lane A, Savin R, Drake L, Berman B, Lucky A, et al. A comparison
of once-daily application of mometasone furoate 0.1% cream compared with twice-daily
hydrocortisone valerate 0.2% cream in pediatric atopic dermatitis patients
who failed to respond to hydrocortisone: mometasone furoate study group. Int
J Dermatol. 1999 Aug;38(8):604-6. No abstract available.
12) Brock W, Cullen SI. Triamcinolone acetonide in flexible collodion for dermatologic
therapy. Arch Dermatol. 1967 Aug;96(2):193-4.
13) Maloney JM, Morman MR, Stewart DM, Tharp MD, Brown JJ, Rajagopalan R. Clobetasol
propionate emollient 0.05% in the treatment of atopic dermatitis. Int J Dermatol.
1998 Feb;37(2):142-4.
14) Patzelt-Wenczler R, Ponce-Poschl E. Proof of Efficacy of Kamillosan cream
in atopic eczema. Eur J Med Res 2000;5:171-175.
15) Freeman S, Howard A, Foley P, Rosen R, Wood G, See JA, Gray S. Efficacy,
cutaneous tolerance and cosmetic acceptability of desonide 0.05% lotion (Desowen)
versus vehicle in the short-term treatment of facial atopic or seborrhoeic
dermatitis. Austral J Dermatol 2002;45:186-189.
16) Vanderploeg DE. Betamethasone dipropionate ointment in the treatment of
psoriasis and atopic dermatitis: a double-blind study. South Med J. 1976 Jul;69(7):862-3.
17) Roth HL, Brown EP. Hydrocortisone valerate. Double-blind comparison with
two other topical steroids. Cutis. 1978 May;21(5):695-8.
18) Bircher AJ, Niederer M, Hohl Ch, Surber Ch. Stealth triamcinolone acetonide
in a phytocosmetic cream. Br J Dermatol. 2002 Mar;146(3):531-2
19) Camacho F, Garcia Bravo B, Diaz Perez JL, Aguirre A, Arnau C, Garcia Barbal
J, et al. A comparative intraindividual double-blind assay between prednicarbate
and fluocortolone in the management of atopic dermatitis. Actas Dermo Sifiliograficas.
1996;87(1-2):59-63.
20) Bleeker J. Double-blind comparison between two new topical corticosteroids,
halcinonide 0.1% and clobetasol propionate cream 0.05%. Curr Med Res Opin.
1975;3(4):225-8.
21) Haneke E. The treatment of atopic dermatitis with methylprednisolone aceponate(mpa),
a new topical corticosteroid. J Dermatol Treat. 1992;3 Suppl 2:13-15.
22) Bagatell FK, Barkoff JR, Cohen HJ, Lasser AE, McCormick GE, Rex IH, et
al. A multi-center comparison of alclometasone dipropionate cream 0.05% and
hydrocortisone cream 1.0% in the treatment of atopic dermatitis. Curr Ther
Res Clin Exp. 1983;33(1):46-52.
23) Gelmetti C, Grimalt R, Del Campo G, Caputo R. Tolerability and efficacy
of topical budesonide in the treatment of atopic dermatitis in pediatric age.
G Ital Dermatol Venereol. 1994;129(3):XIII-XVII.
24) Majerus JP, Reiffers-Mettelock J. Sicorten: a synthetic corticosteroid
for topical treatment of common dermatoses. J Int Med Res. 1986;14(1):46-9.
25) Jorizzo J, Levy M, Lucky A, Shavin J, Goldberg G, Dunlap F, Hinds A,
Strelka L, Baker M, Tuley M, et al. Multicenter trial for long-term safety and efficacy
comparison of 0.05% desonide and 1% hydrocortisone ointments in the treatment
of atopic dermatitis in pediatric patients. J Am Acad Dermatol. 1995 Jul;33(1):74-7.
26) Almeyda J, Burt BW. Double blind controlled study of treatment of atopic
eczema with a preparation of hydrocortisone in a new drug delivery system versus
betamethasone 17-valerate. Br J Dermatol. 1974 Nov;91(5):579-83.
27) Leibsohn E, Bagatell FK. Halcinonide in the treatment of corticosteroid
responsive dermatoses. Br J Dermatol. 1974 Apr;90(4):435-40.
28) Fisher M, Kelly AP. Multicenter trial of fluocinonide in an emollient cream
base. Int J Dermatol. 1979 Oct;18(8):660-4.
29) Yasuda T. Clinical experiences with hydrocortisone 17-butyrate. Dermatologica.
1976;152 Suppl 1:221-9.
30) Binder R, McCleary J. Comparison of fluocinonide in a double-blind study
with betamethasone valerate. Curr Ther Res Clin Exp. 1972 Jan;14(1):35-8.
31) Duke EE, Maddin S, Aggerwal A. Alclometasone dipropionate in atopic dermatitis:
a clinical study. Curr Ther Res Clin Exp. 1983;33(5):769-74.
32) Rajka G, Verjans HL. Hydrocortisone 17-butyrate (Locoid) 0.1% fatty cream
versus desonide (Apolar) 0.1% ointment in the treatment of patients suffering
from atopic dermatitis. J Int Med Res. 1986;14(2):85-90.
33) Veien NK, Hattel T, Justesen O, Norholm A, Verjans HL. Hydrocortisone 17-butyrate
(Locoid) 0.1% cream versus hydrocortisone (Uniderm) 1% cream in the treatment
of children suffering from atopic dermatitis. J Int Med Res. 1984;12(5):310-3.
34) Lassus A. Clinical comparison of alclometasone dipropionate cream 0.05%
with hydrocortisone butyrate cream 0.1% in the treatment of atopic dermatitis
in children. J Int Med Res. 1983;11(5):315-9.
35) el-Hefnawi H, el-Shiemy S, Paris R, Tadros SS. Double-blind paired comparison
clinical trial of halcinonide and hydrocortisone. Cutis. 1978 Jul;22(1):97-9.
36) Bluefarb SM, Howard FM, Leibsohn E, Schlagel CA, Wexler L. Diflorasone
diacetate: vasoconstrictor activity and clinical efficacy of a new topical
corticosteroid. J Int Med Res. 1976;4(6):454-61.
37) Morley N, Fry L, Walker S. Clinical evaluation of clobetasone butyrate
in the treatment of children with atopic eczema, and its effect on plasma corticosteroid
levels. Curr Med Res Opin. 1976;4(3):223-8.
38) Bjornberg A, Hellgren L. [Comparison between 2 steroid dosage forms in
psoriasis and eczema]. Z Hautkr. 1975;Suppl 2:13-5. German.
39) Almeyda J, Fry L. Controlled trial of the treatment of atopic eczema with
a urea-hydrocortisone preparation versus betamethasone 17-valeraete. Br J Dermatol.
1973 May;88(5):493-5.
40) Rampini E. Methylprednisolone aceponate(mpa)-use and clinical experience
in children. J Dermatol Treat.1992;3 Suppl 2:27-9.
41) Hoybye S, Balk Moller S, De Cunha Bang F, Ottevanger V, Veien NK. Continuous
and intermittent treatment of atopic dermatitis in adults with mometasone
furoate vs. hydrocortisone 17-butyrate. Curr Ther Res Clin Exp. 1991;50:67-72.
42) Lassus A. Alclometasone dipropionate cream 0.05% versus clobetasone butyrate
cream 0.05%. A controlled clinical comparison in the treatment of atopic dermatitis
in children. Int J Dermatol. 1984 Oct;23(8):565-6.
43) Sefton J, Kyriakopoulos AA. Comparative efficacy of hydrocortisone valerate
0.2 percent ointment in the treatment of atopic dermatitis. Cutis. 1983 Jul;32(1):89-91,
94.
44) Nolting S. [Treatment with topical corticosteroids in severe or resistant
dermatoses] Derm Beruf Umwelt. 1985;33(4):140-4. German.
45) Van DelRey ML, Geller M, Azulay RD. Estudo duplo-cego sobre a eficacia
e a seguranca do crème de alcometasoma no tratamento de dermatite atopica./
[Double-blind study on the efficacy and safety of alclomethasone cream in the
treatment of atopic dermatitis.] An Bras Dermatol. 1983;58:177-80.
46) Konzelmann M, Harms M. [Diflorasone diacetate cream compared to betamethasone
dipropionate cream in the treatment of eczemas] Schweiz Rundsch Med Prax. 1983
May 17;72(20):709-11. German.
47) Harder F, Rufli T. [Therapy of eczema. Once daily use of diflorasone diacetate
in comparison to thrice daily use of betamethasone-17-valerate] Schweiz Rundsch
Med Prax. 1983 Sep 27;72(39):1240-2. German.
48) Savin RC. Betamethasone dipropionate in psoriasis and atopic dermatitis.
Conn Med. 1976 Jan;40(1):5-7. No abstract available.
49) Ramelet AA, Mauracher E. Treatment of resistant steroid-responsive dermatoses:
a comparison of Diprolene and Neriforte. Clin Trials J 1982;19:298-307.
50) Prado de Oliveira ZN et al. Comparative evaluation of efficacy, tolerability
and safety of 0.1% topical mometasone furoate and 0.05% desonide in the treatment
of childhood atopic dermatitis. Anais Brasileiros de dermatologia.77(1):25-33
51) Lebrun-Vignes B, Legrain V, Amoric J, Taieb A. Comparative study of efficacy
and effect on plasma cortisol levels of micronised desonide cream 0.1 p. 100
versus betamethasone dipropionate cream 0.05 p. 100 In the treatment of childhood
atopic dermatitis. Ann Dermatol Venereol. 2000 Jun-Jul;127(6-7):590-5.
52) Wachs GN, Maibach HI. Co-operative double-blind trial of an antibiotic/corticoid
combination in impetiginized atopic dermatitis. Br J Dermatol. 1976 Sep;95(3):323-8.
53) Hjorth N, Schmidt H, Thomsen K. Fusidic acid plus betamethasone in infected
or potentially infected eczema. Pharmatherapeutica. 1985;4(2):126-31.
54) Wilkinson RD, Leigh DA. Comparative efficacy of betamethasone and either
fusidic acid or neomycin in infected or potentially infected eczema. Curr Ther
Res. 1985;38:177-82.
55) Meenan FO. A double-blind comparative study to compare the efficacy of
Locoid C with Tri-Adcortyl in children with infected eczema. Br J Clin Pract.
1988 May;42(5):200-2.
56) Zienicke H. Topical glucocorticoids and anti-infectives: a rational combination?
Curr Probl Dermatol. 1993;21:186-91.
57) Ramsay CA, Savoie JM, Gilbert M, Gidon M, Kidson P. The treatment of atopic
dermatitis with topical fusidic acid and hydrocortisone acetate. J Eur Acad
Dermatol Venereol. 1996;7 supplT:S15-S22.
58) Anonymous. Treatment of eczemas and infected eczemas. Br J Clin Pract.1967;21(10):505-7.
59) Kaplan RJ, Daman L, Rosenberg EW, Feigenbaum S. Topical use of caffeine
with hydrocortisone in the treatment of atopic dermatitis. Arch Dermatol. 1978
Jan;114(1):60-2.
60) Chapman RS. Treatment of atopic dermatitis. Practitioner. 1979 Nov;223(1337):713-6.
61) Noren P, Melin L. The effect of combined topical steroids and habit-reversal
treatment in patients with atopic dermatitis. Br J Dermatol. 1989 Sep;121(3):359-66.
62) Hanifin JM, Hebert AA, Mays SR, Paller AS, Sherertz EF, Wagner AM, et al.
Effects of a low-potency corticosteroid lotion plus a moisturizing regimen
in the treatment of atopic dermatitis. Curr Ther Res Clin Exp 1998;59(4):227-33.
63) Cato A, Swinehart JM, Griffin EI, Sutton L, Kaplan AS. Azone enhances clinical
effectiveness of an optimized formulation of triamcinolone acetonide in atopic
dermatitis. Int J Dermatol. 2001 Mar;40(3):232-6.
64) Wahn U, Bos JD, Goodfield M, Caputo R, Papp K, Manjra A, Dobozy A, Paul
C, Molloy S, Hultsch T, Graeber M, Cherill R, de Prost Y. Efficacy and safety
of pimecrolimus cream in the long-term management of atopic dermatitis in children.
Pediatrics. 2002 Jul;110(1 Pt 1):e2.
65) Griffiths CE, Van Leent EJ, Gilbert M, Traulsen J. Randomized comparison
of the type 4 phosphodiesterase inhibitor cipamfylline cream, cream vehicle
and hydrocortisone 17-butyrate cream for the treatment of atopic dermatitis.
Br J Dermatol. 2002 Aug;147(2):299-307.
66) Luger T, Van Leent EJ, Graeber M, Hedgecock S, Thurston M, Kandra A, et
al. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol. 2001 Apr;144(4):788-94.
67) Hiratsuka S, Yoshida A, Ishioka C, Kimata H. Enhancement of in vitro spontaneous
IgE production by topical steroids in patients with atopic dermatitis. J Allergy
Clin Immunol. 1996 Jul;98(1):107-13.
68) Munkvad M. A comparative trial of Clinitar versus hydrocortisone cream
in the treatment of atopic eczema. Br J Dermatol. 1989 Dec;121(6):763-6.
69) Wolkerstorfer A, Visser RL, De Waard van der Spek FB, Mulder PG, Oranje
AP. Efficacy and safety of wet-wrap dressings in children with severe atopic
dermatitis: influence of corticosteroid dilution. Br J Dermatol. 2000 Nov;143(5):999-1004.
70) Pei AY, Chan HH, Ho KM. The effectiveness of wet wrap dressings using 0.1%
mometasone furoate and 0.005% fluticasone proprionate ointments in the treatment
of moderate to severe atopic dermatitis in children. Pediatr Dermatol. 2001
Jul-Aug;18(4):343-8.
71) Schnopp C, Holtmann C, Stock S, Remling R, Folster-Holst R, Ring J,
Abeck D. Topical steroids under wet-wrap dressings in atopic dermatitis--a vehicle-controlled
trial. Dermatology. 2002;204(1):56-9.
72) Thomas KS, Armstrong S, Avery A, Po AL, O'Neill C, Young S, Williams
HC. randomized controlled trial of short bursts of a potent topical corticosteroid
versus prolonged use of a mild preparation for children with mild or moderate
atopic eczema. BMJ. 2002 Mar 30;324(7340):768.
73) Berth-Jones J, Damstra RJ, Golsch S, Livden JK, Van Hooteghem O, Allegra
F, Parker CA. Twice weekly fluticasone propionate added to emollient maintenance
treatment to reduce risk of relapse in atopic dermatitis: randomized, double
blind, parallel group study. BMJ. 2003 Jun 21;326(7403):1367
74) Veien NK, Larsen P, Thestrup-pedersen K, Schou G. Long-term intermittent
treatment of chronic hand eczema with mometasone furoate. Brit J Dermatol 1999:140:882-886.
75) Faergemann J, Christensen O, Sjovall P, Johnsson A, Hersle K, Nordin P,
Edmar B, Svensson A. An open study of efficacy and safety of long-term treatment
with mometasone furoate fatty cream in the treatment of adult patients with
atopic dermatitis. J Eur Acad Dermatol Venereol. 2000 Sep;14(5):393-6
76) Friedlander SF, Hebert AA, Allen DB. Safety of fluticasone propionate cream
0.05% for the treatment of severe and extensive atopic dermatitis in children
as young as 3 months. J Am Acad Dermatol. 2002 Mar;46(3):387-93.
77) Hanifin J, Gupta AK, Rajagopalan R Intermittent dosing of fluticasone propionate
cream for reducing the risk of relapse in atopic dermatitis patients. Br J
Dermatol. 2002 Sep;147(3):528-37.
78) Korting HC, Unholzer A, Schafer-Korting M, Tausch I, Gassmueller J, Nietsch
KH. Different skin thinning potential of equipotent medium-strength glucocorticoids.
Skin Pharmacol Appl Skin Physiol. 2002 Mar-Apr;15(2):85-91.
79) Kerscher MJ, Korting HC, Mehringer L, Matzig R. 0.05% clobetasol 17-propionate
cream and ointment but not the corresponding 0.1% triamcinolone acetonide preparations
increase skin surface roughness: a possible dissociation of unwanted epidermal
and dermal effects. Skin Pharmacol. 1996;9(2):120-3.
80) Korting HC, Vieluf D, Kerscher M. 0.25% prednicarbate cream and the corresponding
vehicle induce less skin atrophy than 0.1% betamethasone-17-valerate cream
and 0.05% clobetasol-17-propionate cream. Eur J Clin Pharmacol. 1992;42(2):159-61.
81) Kerscher MJ, Hart H, Korting HC, Stalleicken D. In vivo assessment of the
atrophogenic potency of mometasone furoate, a newly developed chlorinated potent
topical glucocorticoid as compared to other topical glucocorticoids old and
new. Int J Clin Pharmacol Ther. 1995 Apr;33(4):187-9.
82) Kerscher MJ, Korting HC. Topical glucocorticoids of the non-fluorinated
double-ester type. Lack of atrophogenicity in normal skin as assessed by high-frequency
ultrasound. Acta Derm Venereol. 1992;72(3):214-6.
83) Furue M, Terao H, Rikihisa W, Urabe K, Kinukawa N, Nose Y, Koga T. Clinical
dose and adverse effects of topical steroids in daily management of atopic
dermatitis. Br J Dermatol. 2003 Jan;148(1):128-33.
84) Corazza M, Mantovani L, Maranini C, Bacilieri S, Virgili A. Contact sensitization
to corticosteroids: increased risk in long term dermatoses. Eur J Dermatol.
2000 Oct-Nov;10(7):533-5.
85) Matsuda K, Katsunuma T, Iikura Y, Kato H, Saito H, Akasawa A. Adrenocortical
function in patients with severe atopic dermatitis. Ann Allergy Asthma Immunol.
2000 Jul;85(1):35-9.
86) Ellison JA, Patel L, Ray DW, David TJ, Clayton PE. Hypothalamic-pituitary-adrenal
function and glucocorticoid sensitivity in atopic dermatitis. Pediatrics. 2000
Apr;105(4 Pt 1):794-9.
87) Hida T, Tano Y, Okinami S, Ogino N, Inoue M. Multicenter retrospective
study of retinal detachment associated with atopic dermatitis. Jpn J Ophthalmol.
2000 Jul-Aug;44(4):407-18.
88) Koopmans B, Lasthein Andersen B, Mork NJ, Austad J, Suhonen RE. Multicentre
randomized double-blind study of locoid lipocream fatty cream twice daily versus
locoid lipocream once daily and loco-base once daily. J Dermatol Treat. 1995;6(2):103-6.
89) Lebwohl M. Efficacy and safety of fluticasone propionate ointment, 0.005%, in
the treatment of eczema. Cutis1996;57;no2S:62-68.
90) Lawlor F, Black AK, Geaves M. Prednicarbate 0.25% ointment in the treatment
of atopic dermatitis: a vehicle-controlled double-blind study. J Dermatol Treat
1995; 6: 233-235.
91) Patel L, Clayton PE, Addison GM, Price DA, David TJ. Adrenal function following
topical steroid treatment in children with atopic dermatitis. Br J Dermatol.
1995;132: 950-955.
92) Hoare C, Li Wan Po A, Williams H. Systematic review of treatment of atopic
eczema. Health Technol Assess 2000;4(37)
93) Long CC, Finlay AY. The finger-tip unit ? a new practical measure. Clin
Exp Dermatol 1991;16: 444-447
94) Long CC, Mills CM, Finlay AY, A practical guide to topical therapy in children.
Brit J Dermatol 1998;138: 293-296 |
|
![XeChOpΓ@]Ώ\κ](image/link_01.gif)
![]Ώ\Μ©ϋ](../image/link_02.gif){kind=small}
![]Ώ@Μ©ϋ](../image/link_03.gif){kind=small}
